secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANGOCEUTICALS, INC. (MGRX)
CIK:        0001938046
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001493152-25-019941
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 1.02, 2.03, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mangoceuticals leases Dallas office and separates from COO Hammer with severance
--------------------------------------------------------------------------------

- Enters 5-year lease for 2,467 sq ft Suite 245 at 17130 Dallas Parkway; base rent $4,852/mo + operating expenses.
- COO Amanda Hammer terminated effective Oct 22, 2025; receives 9 months' salary in equal installments starting Nov 1, 2025.
- Indigo Capital LP converts 500 Series B shares ($500,000 stated value) into 366,667 common shares at $1.50/sh conversion price.
- Platinum Point Capital converts 32 Series B shares ($35,200 stated value) into 23,466 common shares on Oct 16, 2025.
- Employment agreement with Hammer terminated; no material termination penalties incurred beyond severance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225019941/0001493152-25-019941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1938046/000149315225019941/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer